HepQuant SHUNT Liver Diagnostic Test
Hepquant, LLC · Decision date Jun 18, 2026
What did the FDA approve?
FDA records P220016 as an original PMA application. The recorded decision is approval, dated Jun 18, 2026.
FDA approval order statement
Approval for HepQuant SHUNT Liver Diagnostic TestThe HepQuant SHUNT Liver Diagnostic Test is designed for the quantitative detection of 13C-cholate and d4-cholate in human serum from blood samples collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The assay generates a Disease Severity Index (DSI) score from the clearance of 13C-cholate and d4-cholate. Sample analysis is conducted by the HepQuant Analytical Test Laboratory.A DSI score below the validated threshold can be used in patients with compensated cirrhosis (Child Pugh Class A), age 22 years or older, undergoing screening or surveillance for esophageal varices to identify those patients unlikely to have large esophageal varices. The DSI score aids in identifying patients unlikely to require esophagogastroduodenoscopy (EGD) at the time of testing.The HepQuant SHUNT Liver Diagnostic Test is not a stand-alone test and should be used in conjunction with other clinical and laboratory findings.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Clinical Chemistry
- Decision date
- Jun 18, 2026
Regulatory record facts
- Identifier
- P220016
- Regulatory pathway
- Premarket approval application
- Applicant
- Hepquant, LLC
- Product code
- SIO
- Decision code
- APPR
- Decision date
- Jun 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test for Esophageal Varices.
- Applicant
- Hepquant, LLC
- Product code
- SIO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220016 received
Application receipt date recorded by FDA.
P220016 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P220016. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hepquant, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 12635 E. Montview Blvd., Suite 175l1, Aurora, CO, 80045
Sources and methodology
- Original FDA record: P220016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records